Karyopharm Therapeutics Inc (KPTI) Upgraded to “Hold” by Zacks Investment Research

Karyopharm Therapeutics Inc (NASDAQ:KPTI) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “

A number of other equities analysts have also recently issued reports on KPTI. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a report on Friday. Canaccord Genuity reissued a “buy” rating and issued a $20.00 target price on shares of Karyopharm Therapeutics in a report on Monday, March 13th. Wedbush reissued an “outperform” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a report on Saturday, March 4th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $14.00 target price on shares of Karyopharm Therapeutics in a report on Monday, March 13th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $13.76.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) opened at 10.67 on Tuesday. The stock’s market cap is $440.06 million. The stock’s 50 day moving average price is $10.71 and its 200 day moving average price is $9.69. Karyopharm Therapeutics has a 52 week low of $6.27 and a 52 week high of $14.63.

Your IP Address:

Several large investors have recently made changes to their positions in KPTI. Palo Alto Investors LLC raised its stake in shares of Karyopharm Therapeutics by 3.7% in the fourth quarter. Palo Alto Investors LLC now owns 3,200,396 shares of the company’s stock valued at $30,084,000 after buying an additional 114,547 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its stake in shares of Karyopharm Therapeutics by 12.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 21,911 shares of the company’s stock valued at $206,000 after buying an additional 2,460 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $273,000. Dimensional Fund Advisors LP raised its stake in shares of Karyopharm Therapeutics by 347.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 261,055 shares of the company’s stock valued at $2,454,000 after buying an additional 202,714 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Karyopharm Therapeutics by 6.6% in the fourth quarter. State Street Corp now owns 406,103 shares of the company’s stock valued at $3,820,000 after buying an additional 25,015 shares during the last quarter. Institutional investors own 56.97% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its segment is the business of discovering, developing and commercializing drugs to treat cancer and certain other major diseases.

5 Day Chart for NASDAQ:KPTI

Receive News & Ratings for Karyopharm Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply